Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Merck
Medtronic
McKinsey
Express Scripts

Last Updated: September 26, 2022

Details for Patent: 7,569,230


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,569,230 protect, and when does it expire?

Patent 7,569,230 protects ORAVERSE and is included in one NDA.

This patent has sixteen patent family members in twelve countries.

Summary for Patent: 7,569,230
Title:Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Abstract:The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.
Inventor(s): Chen; Andrew X (San Diego, CA), Knowles; Julius (Del Mar, CA), Weber; Eckard (San Diego, CA)
Assignee: Novalar Pharmaceuticals, Inc. (San Diego, CA)
Application Number:11/611,504
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form; Device;

Drugs Protected by US Patent 7,569,230

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes See Plans and Pricing See Plans and Pricing A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,569,230

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003247568 See Plans and Pricing
Brazil 0311965 See Plans and Pricing
Brazil PI0311965 See Plans and Pricing
Canada 2489526 See Plans and Pricing
China 100391460 See Plans and Pricing
China 1688312 See Plans and Pricing
European Patent Office 1539170 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Mallinckrodt
Colorcon
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.